Isabelle Girault

Novel agonist monoclonal antibody targeting GPCR to decrease neutrophil accumulation and initiate resolution of chronic inflammation 2310040

Charles‐Antoine Coupet, Charlène Trilleaud, Julien Taurelle, Clémence Gaudin et autres

fr (code pays fourni par la source)

Challenges for teachers in getting their students to design experiments: outcome of a collaborative research project

Laure Mondelain, Isabelle Girault, Claire Wajeman

Abstract 6360: A tumor agnostic composite gene expression signature identifies three groups of patients treated with immune checkpoint blockade with distinct clinical outcome

Mehdi Lamkhioued, Guillaume Robert-Siegwald, Roxane M. Pommier, Camille Brodin et autres

fr (code pays fourni par la source)

Abstract 7293: First in class Anti-CLEC-1A myeloid checkpoint antibodies for the treatment of solid tumors with monotherapy and combination therapy efficacies

Etienne Foucher, Mylène Déramé, Justine Durand, Marion Drouin et autres

fr (code pays fourni par la source)

Abstract 6342: Anti-tumor in vivo efficacy of different classes of anti-CLEC-1 myeloid checkpoint antibodies in monotherapy and in combination with chemotherapeutic agents

Aurore Morello, Mylène Déramé, Marion Drouin, Emmanuelle Wilhelm et autres

fr (code pays fourni par la source)

493 Identification of different classes of antagonist monoclonal antibodies targeting the myeloid checkpoint CLEC-1 and their associated anti-tumoralin vivoefficacies in humanized preclinical models

Irène Baccelli, Caroline Mary, Stéphanie Neyton, Marion Drouin et autres

fr (code pays fourni par la source)

1370 Anti-PD-1/IL-7v immunocytokine favors proliferation & survival of TCF1+ stem like memory T cells and a durable in vivo efficacy in monotherapy or using combinatorial strategy

Aurore Morello, Justine Durand, Margaux Seité, Isabelle Girault et autres

fr (code pays fourni par la source)

ChemR23 activation reprograms macrophages toward a less inflammatory phenotype and dampens carcinoma progression

Margot Lavy, Vanessa Gauttier, Alison Dumont, Florian Chocteau et autres

fr (code pays fourni par la source)

Abstract 2955: Anti-PD-1/IL-7v bispecific antibody promotes TCF1+ stem like CD8 T cells expansion and long-lasting in vivo efficacy

Aurore Morello, Margaux Seité, Justine Durand, Isabelle Girault et autres

fr (code pays fourni par la source)

Abstract 2129: Predictive response biomarkers from Phase I clinical trial of a SIRPalpha inhibitor BI765063, stand-alone and in combination with ezabenlimab, a PD1 inhibitor, in patients with advanced solid tumors

Stéphane Champiat, Philippe A. Cassier, Nuria Kotecki, Carlos Gomez-Roca et autres

fr, be, us (code pays fourni par la source)

Abstract 6358: CLEC-1 inhibitory myeloid checkpoint blockade enhances antitumor responses and tumor phagocytosis by macrophages

Vanessa Gauttier, Irène Baccelli, Marion Drouin, Isabelle Girault et autres

fr (code pays fourni par la source)

Abstract 6365: TRIM21 is a novel endogenous partner of the inhibitory myeloid checkpoint CLEC-1 involved in tumor antigen cross-presentation

Irène Baccelli, Vanessa Gauttier, Marion Drouin, Caroline Mary et autres

fr (code pays fourni par la source)